{"id":"rez","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"patents":[{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Mar 14, 2033","territory":"US","drugProduct":true,"patentNumber":"10702573","drugSubstance":true},{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Mar 14, 2033","territory":"US","drugProduct":true,"patentNumber":"9526835","drugSubstance":true},{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Mar 2, 2032","territory":"US","drugProduct":true,"patentNumber":"8722619","drugSubstance":true},{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Jul 14, 2038","territory":"US","drugProduct":true,"patentNumber":"11197909","drugSubstance":true},{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Mar 2, 2032","territory":"US","drugProduct":true,"patentNumber":"11654196","drugSubstance":true},{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Mar 15, 2037","territory":"US","drugProduct":true,"patentNumber":"11712459","drugSubstance":false},{"applNo":"N217417","source":"FDA Orange Book","status":"Active","expires":"Jul 11, 2038","territory":"US","drugProduct":true,"patentNumber":"11819533","drugSubstance":true}],"_fixedAt":"2026-03-30T12:38:38.674709","_dailymed":{"setId":"90073508-6dca-4d27-aa5a-ed837737c35b","title":"REZZAYO (REZAFUNGIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MELINTA THERAPEUTICS, LLC]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD19, REZ triggers the destruction of B cells, which are a type of immune system cell that can contribute to various diseases. This mechanism is particularly effective in treating certain types of blood cancers.","oneSentence":"REZ is a monoclonal antibody that targets the CD19 protein on B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:28:25.879Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"},{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory mantle cell lymphoma"}]},"_fixedFields":["patents(7)"],"trialDetails":[{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT01802814","phase":"PHASE3","title":"International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-05","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":700},{"nctId":"NCT00749723","phase":"PHASE2, PHASE3","title":"Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children","status":"COMPLETED","sponsor":"University Hospital, Bonn","startDate":"2006-02-01","conditions":"Recurrent Brain Tumors, Supratentorial PNETs, Medulloblastomas","enrollment":174},{"nctId":"NCT00114348","phase":"PHASE4","title":"ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2003-08","conditions":"Lymphoblastic Leukemia, Acute, Lymphoma, Non-Hodgkin","enrollment":338},{"nctId":"NCT00023374","phase":"NA","title":"TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2000-08","conditions":"Tuberculosis","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_patentsChecked":true,"_approvalHistory":[],"publicationCount":463,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"REZ","genericName":"REZ","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Small molecule","firstApprovalDate":"","aiSummary":"REZ is a monoclonal antibody that targets the CD19 protein on B cells. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma, Relapsed or refractory mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}